首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1766257

麻疹、腮腺炎、德國麻疹疫苗市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Measles, Mumps, Rubella Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年06月03日 | 出版商:

Global Market Insights Inc. | 英文 90 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年，全球麻疹、腮腺炎和德國麻疹疫苗市場規模達20億美元，預計2034年將以8.3%的複合年成長率成長，達到43億美元。這一成長可歸因於多種因素，包括對兒童免疫接種的日益重視、疫情爆發的增加以及全球衛生計劃的廣泛開展。在中低收入國家，這個問題依然緊迫，由於資源有限且資金不足，需要有針對性的疫苗接種計畫。此外，政府加大對旨在實現群體免疫的大規模疫苗接種活動的投入，也顯著促進了市場發展，尤其是在發展中地區。

聯合疫苗和耐熱疫苗的普及減少了對冷鏈基礎設施的依賴，從而提高了偏遠地區的疫苗可及性，並提升了整體免疫效果。疫苗接種意識的提高、醫療基礎設施的改善以及更具包容性的國家免疫計劃，正在推動全球免疫接種率的提高。此外，新興經濟體出生率的上升以及麻腮風（MMR）疫苗被納入常規疫苗接種計劃，也擴大了市場的目標人口。旨在更好地控制疾病的增強型三價和四價疫苗的持續研發，也進一步支撐了市場的成長。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	20億美元
預測值	43億美元
複合年成長率	8.3%

四價疫苗市場規模在2024年達到9.49億美元。四價疫苗將多種疫苗合而為一，因其簡化了疫苗接種程序並提高了依從性（尤其是在兒童中）而日益受到歡迎。由於四價疫苗保護範圍更廣且更容易接種，目前已被納入全球各國（包括已開發經濟體和新興經濟體）的國家免疫計畫。四價疫苗不僅能預防麻疹和德國麻疹，還能預防水痘，這推動了MMRV疫苗的需求。冷鏈物流的改進以及世界衛生組織等全球衛生組織的支持也促進了四價疫苗在全球的普及，使其成為市場擴張的關鍵驅動力。

預計到2034年，醫院和診所市場規模將達到21億美元。醫院和診所在麻腮風（MMR）疫苗市場中佔據主導地位，這主要歸功於它們積極參與免疫接種活動並提供豐富的兒科服務。這些醫療機構憑藉著完善的冷鏈基礎設施和經驗豐富的專業人員，成為城市和半城市地區疫苗接種的關鍵中心，確保疫苗的妥善儲存和配送。此外，在疫情爆發期間，許多國家都依賴醫院作為大規模免疫接種計畫的主要樞紐，這進一步提升了該領域的市場佔有率。新興市場中初級醫療保健中心數量的不斷增加以及公私合作的不斷加強，也促進了該領域的成長。

2024年，美國麻疹、腮腺炎、德國麻疹疫苗市場規模達7.261億美元。儘管該市場已成熟且受到嚴格監管，但其發展仍受到公共衛生建議、學校免疫接種強制要求以及局部疫情應對活動的驅動。儘管疫苗接種猶豫不決偶爾會造成一些挫折，但在政府資金、價格調控以及兒童疫苗接種計劃（VFC）等項目的支持下，兒童疫苗接種率依然保持高位。美國在疫苗研發和出口領域也繼續發揮主導作用，進一步增強了其在全球免疫接種工作中的影響力。

全球麻疹、腮腺炎和德國麻疹疫苗市場的公司採取的關鍵策略包括利用疫苗傳遞技術進步，例如開發聯合疫苗和低劑量疫苗，以提高患者的依從性。他們也致力於透過增強冷鏈基礎設施來提高疫苗的可及性，並與全球衛生組織和政府建立強力的合作，以確保疫苗能夠覆蓋服務匱乏的地區。此外，他們還投資研發，推出更新、更有效的疫苗配方，以提供更廣泛的傳染病防護，從而增強其市場佔有率和長期永續性。

產業生態系統分析
- 供應商格局
- 每個階段的增值
- 影響價值鏈的因素
產業衝擊力
- 成長動力
  - 透過國家疫苗接種計劃提高免疫覆蓋率
  - 發展中經濟體兒科人口不斷增加
  - 疫苗配方和生產效率的進步
- 產業陷阱與挑戰
  - 嚴格的法規核准流程
  - 偏遠地區疫苗接種機會有限
- 市場機會
  - 擴大疫苗分發的公私部門合作夥伴關係
  - 聯合疫苗需求不斷增加，以減輕注射負擔
成長潛力分析
監管格局
- 北美洲
- 歐洲
- 亞太地區
波特的分析
PESTEL分析
技術和創新格局
- 當前的技術趨勢
- 新興技術
價格趨勢
- 按地區
- 按疫苗類型
未來市場趨勢
技術和創新格局
- 當前的技術趨勢
- 新興技術
貿易統計（HS編碼）
- 主要進口國
- 主要出口國

第4章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
關鍵進展
- 併購
- 夥伴關係和合作
- 新產品發布
- 擴張計劃

第5章：市場估計與預測：按疫苗類型，2021-2034

主要趨勢
單價
三價疫苗（MMR聯合疫苗）
四價

第6章：市場估計與預測：按目標族群，2021-2034 年

主要趨勢
嬰兒和兒童
成年人

第7章：市場估計與預測：依最終用途，2021-2034

主要趨勢
醫院和診所
政府和公共衛生計劃
其他最終用途

第8章：市場估計與預測：按地區，2021-2034

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第9章：公司簡介

Actiza Pharmaceutical Pvt. Ltd.
Beijing Institute of Biological Products
Biological E
GSK
Merck
Minhai Bio
Sanofi
Serum Institute of India
Shanghai Institute of Biological Products
Sinovac
Zydus Life Science

簡介目錄

Product Code: 14061

The Global Measles, Mumps, Rubella Vaccine Market was valued at USD 2 billion in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 4.3 billion by 2034. This expansion can be attributed to several factors, including the growing emphasis on childhood immunization, a rise in outbreaks, and widespread global health initiatives. The issue remains pressing in lower-middle-income nations, where limited resources and inadequate funding necessitate targeted vaccination programs. Furthermore, the increasing government investment in mass vaccination drives aimed at achieving herd immunity is significantly boosting the market, especially in developing regions.

Measles, Mumps, Rubella Vaccine Market - IMG1

The availability of combination vaccines and thermostable vaccines, which reduce dependence on cold-chain infrastructure, is enhancing vaccine accessibility in remote areas, improving overall efficacy. Rising vaccination awareness, better healthcare infrastructure, and more inclusive national immunization programs are contributing to higher immunization rates globally. Additionally, the increasing birth rates in emerging economies and the integration of MMR vaccines into routine vaccination schedules are expanding the market's target demographic. The ongoing development of enhanced trivalent and quadrivalent vaccines, designed for better disease control, is further supporting market growth.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$2 Billion
Forecast Value	$4.3 Billion
CAGR	8.3%

The tetravalent segment was valued at USD 949 million in 2024. Tetravalent vaccines, which combine multiple vaccinations into one shot, are gaining popularity as they simplify vaccination schedules and improve compliance, particularly in children. These vaccines are now being integrated into national immunization programs worldwide, both in developed and emerging economies, as they offer broader protection and are easier to administer. Their ability to address not only measles and rubella but also varicella, is driving demand for MMRV formulations. Improved cold-chain logistics and support from global health organizations like the WHO are also contributing to the increased adoption of tetravalent vaccines globally, making this segment a key driver of market expansion.

The hospitals and clinics segment is projected to reach USD 2.1 billion by 2034. Hospitals and clinics maintain a dominant role in the MMR vaccine market, largely due to their involvement in immunization campaigns and the range of pediatric services they offer. These healthcare facilities are key centers for vaccine administration in both urban and semi-urban areas, thanks to their well-established cold chain infrastructure and skilled personnel who ensure proper storage and delivery of vaccines. Moreover, during epidemic outbreaks, many nations rely on hospitals as primary hubs for mass immunization programs, further boosting this segment's market share. The expanding number of primary healthcare centers and increasing public-private partnerships in emerging markets also contribute to the growth of this segment.

United States Measles, Mumps, Rubella Vaccine Market was valued at USD 726.1 million in 2024. While the market is mature and heavily regulated, it is still driven by public health recommendations, school immunization mandates, and campaigns responding to localized outbreaks. Although vaccine hesitancy has caused occasional setbacks, pediatric vaccination rates remain high, supported by government funding, controlled pricing, and programs like Vaccines for Children (VFC). The U.S. also continues to play a leading role in vaccine development and exportation, reinforcing its influence on global immunization efforts.

Key strategies adopted by companies in the Global Measles, Mumps, Rubella Vaccine Market include leveraging technological advancements in vaccine delivery, such as the development of combination vaccines and those requiring fewer doses, to increase patient compliance. They also focus on improving accessibility through enhanced cold-chain infrastructure and establishing strong collaborations with global health organizations and governments to ensure vaccines reach underserved regions. Moreover, they invest in research and development to introduce newer, more effective vaccine formulations that provide broader protection against infectious diseases, enhancing both their market presence and long-term sustainability.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis
2.2 Key market trends
- 2.2.1 Regional
- 2.2.2 Vaccines type
- 2.2.3 Targeted population
- 2.2.4 End use
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising immunization coverage through national vaccination programs
  - 3.2.1.2 Increasing pediatric population in developing economies
  - 3.2.1.3 Advancements in vaccine formulation and production efficiency
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory approval processes
  - 3.2.2.2 Limited access to vaccines in remote regions
- 3.2.3 Market opportunities
  - 3.2.3.1 Expanding public-private partnerships for vaccine distribution
  - 3.2.3.2 Growing demand for combination vaccines to reduce injection burden
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
3.5 Porter's analysis
3.6 PESTEL analysis
3.7 Technology and innovation landscape
- 3.7.1 Current technological trends
- 3.7.2 Emerging technologies
3.8 Price trends
- 3.8.1 By region
- 3.8.2 By vaccines type
3.9 Future market trends
3.10 Technology and innovation landscape
- 3.10.1 Current technological trends
- 3.10.2 Emerging technologies
3.11 Trade statistics (HS code)
- 3.11.1 Major importing countries
- 3.11.2 Major exporting countries

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Mergers and acquisitions
- 4.6.2 Partnerships and collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccines Type, 2021-2034 ($ Mn)

5.1 Key trends
5.2 Monovalent
5.3 Trivalent (combined MMR)
5.4 Tetravalent

Chapter 6 Market Estimates and Forecast, By Targeted Population, 2021-2034 ($ Mn)

6.1 Key trends
6.2 Infants and children
6.3 Adults

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Government and public health programs
7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE